Edition:
United Kingdom

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

115.76USD
15 Dec 2017
Change (% chg)

$2.67 (+2.36%)
Prev Close
$113.09
Open
$114.07
Day's High
$116.54
Day's Low
$112.62
Volume
1,593,098
Avg. Vol
640,169
52-wk High
$149.17
52-wk Low
$96.18

Select another date:

Fri, Dec 8 2017

Elliott Management seeks changes at Alexion - NYT

U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals , is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

UPDATE 2-Elliott Management seeks changes at Alexion - NYT

Dec 8 U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

CORRECTED-Elliott Management seeks changes at Alexion - NYT (Dec. 7)

Dec 7 U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

BRIEF-Alexion And Halozyme Enter License Agreement For ENHANZE Technology

* ALEXION AND HALOZYME ENTER LICENSE AGREEMENT FOR ENHANZE TECHNOLOGY Source text for Eikon: Further company coverage:

BRIEF-Alexion receives new Japanese patent for Soliris

* Alexion receives new Japanese patent for Soliris® (eculizumab), extending patent protection into 2027 and strengthening global patent portfolio Source text for Eikon: Further company coverage:

BRIEF-Alexion reports Q3 non-GAAP earnings per share of $1.44

* Q3 earnings per share view $1.32 -- Thomson Reuters I/B/E/S

RPT-BRIEF-Alexion announces interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

BRIEF-Interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

Alexion Pharma to lay off 20 percent of workforce

Alexion Pharmaceuticals Inc said on Tuesday it would lay off about 20 percent of its workforce and sharpen its focus on its core rare disease drugs business, as it looks to restore investor confidence.

UPDATE 2-Alexion Pharma to lay off 20 pct of workforce

* Drugmaker's shares down slightly (Adds details, analyst comment, updates share price)

Select another date: